Back to top
more

Grifols (GRFS)

(Delayed Data from NSDQ)

$10.72 USD

10.72
554,397

-0.06 (-0.56%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $10.72 0.00 (0.00%) 4:50 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 246)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

New Strong Sell Stocks for July 31st

by Zacks Equity Research

CELZ, GRFS and WHR have been added to the Zacks Rank #5 (Strong Sell) List on July 31, 2025.

Ekta Bagri headshot

Will Strong Asceniv Sales Drive ADMA Biologics Further?

by Ekta Bagri

ADMA rides on record Asceniv sales and FDA-backed yield boost, but valuation concerns and EPS downgrades cloud its outlook.

Zacks Equity Research

ADMA Looks to Expand Asceniv's Label: Will This Boost Sales?

by Zacks Equity Research

ADMA surges on soaring Asceniv demand and eyes pediatric label expansion to widen its immunodeficiency treatment reach.

Ekta Bagri headshot

ADMA Stock Gains 17% in Three Months: Buy, Sell or Hold?

by Ekta Bagri

ADMA rises on strong Asceniv demand and boosted 2025-2026 guidance. However, valuation warrants investor caution.

Zacks Equity Research

Grifols (GRFS) Is Up 2.47% in One Week: What You Should Know

by Zacks Equity Research

Does Grifols (GRFS) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

Is Grifols (GRFS) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

GRFS vs. STVN: Which Stock Is the Better Value Option?

by Zacks Equity Research

GRFS vs. STVN: Which Stock Is the Better Value Option?

Ekta Bagri headshot

ADMA Biologics vs. Grifols: Which Plasma Therapy Stock Is the Better Buy?

by Ekta Bagri

At current levels, GRFS scores over ADMA with cheaper valuation, a broad portfolio, and strong EPS growth estimates despite the latter's robust Asceniv-driven momentum.

Zacks Equity Research

GRFS or NBIX: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

GRFS vs. NBIX: Which Stock Is the Better Value Option?

Ekta Bagri headshot

ADMA's Q1 Earnings and Revenues Miss: Buy, Sell or Hold the Stock?

by Ekta Bagri

ADMA Biologics misses on Q1 earnings and revenues. Nonetheless, the growth prospects remain strong as the company raises its revenue guidance for 2025. We recommend the stock to prospective investors.

Ekta Bagri headshot

Should ADMA Biologics Stock Be in Your Portfolio Pre-Q1 Earnings?

by Ekta Bagri

Strong performance of Asceniv continues to boost ADMA. We recommend the stock to investors due to its solid long-term fundamentals.

Zacks Equity Research

Will ADMA Biologics Stock Continue Its Momentum in 2025?

by Zacks Equity Research

ADMA continues to maintain momentum in 2025 after its stupendous performance in 2024. Strong demand for Asceniv should fuel growth.

Ekta Bagri headshot

ADMA Loses 8.9% in a Month: How Should You Play the Stock?

by Ekta Bagri

ADMA Biologics' shares lose 8.9% in a month after putting up a phenomenal performance in the past 12 months. While the prospects remain sound, the exceptional rally witnessed by the stock might limit any further gain.

Zacks Equity Research

ADMA Stock Catapults 275.7% in a Year: How Should You Play the Stock?

by Zacks Equity Research

ADMA Biologics performance in the past twelve months has been phenomenal. While the prospects remain sound, the exceptional rally witnessed by the stock might limit any further gain.

Ekta Bagri headshot

ADMA Stock Falls 19% From Its 52-Week High: Should You Buy the Dip?

by Ekta Bagri

ADMA Biologics has performed phenomenally in 2024. Given its strong trajectory, we recommend investors use any dip in the stock price as a buying opportunity.

Zacks Equity Research

Grifols Stock Declines After Brookfield Drops Buyout Offer

by Zacks Equity Research

Brookfield decides to drop its buyout offer for GRFS following discrepancies over the company's valuation.

Zacks Equity Research

Grifols' Board Rejects Brookfield's Buyout Offer, Stock Down 8%

by Zacks Equity Research

Per GRFS, Brookfield's offer to buy its entire outstanding share capital for 6.45 billion euros significantly undervalues GRFS' prospects and long-term potential.

Zacks Equity Research

Should ADMA Biologics Stock Be in Your Portfolio Pre-Q3 Earnings?

by Zacks Equity Research

ADMA is having a stupendous run in 2024 so far on strong performance of Asceniv and high growth prospects.

Ekta Bagri headshot

ADMA Biologics Stock Skyrockets 262.1% YTD: How to Play the Stock?

by Ekta Bagri

ADMA stock rallies 262.1% in the year-to-date period on strong performance and high growth prospects. It recently hit its 52-week high with more room for growth.

Ekta Bagri headshot

ADMA Biologics Stock Soars 76.2% in 3 Months: Right Time to Invest?

by Ekta Bagri

ADMA stock surges 76.2% in three months on strong performance and high growth prospects. It recently hit its 52-week high with more room for growth.

Zacks Equity Research

Why Grifols (GRFS) Stock Price Moved Up 7% on Wednesday

by Zacks Equity Research

A Bloomberg article suggests that Brookfield Asset Management is in discussions with banks to raise nearly $11 billion to fund the takeover of Spain-based Grifols (GRFS).

Ekta Bagri headshot

ADMA Biologics (ADMA) Hits 52-Week High: More Room to Grow?

by Ekta Bagri

The ADMA Biologics (ADMA) stock surges in a month on impressive second-quarter results. It has recently hit its 52-week high with more room for growth.

Zacks Equity Research

Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FBT

Zacks Equity Research

Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?

by Zacks Equity Research

Sector ETF report for FBT

Zacks Equity Research

GRFS or ZTS: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

GRFS vs. ZTS: Which Stock Is the Better Value Option?